By Professor Bruce James Brew

Journal articles

Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA, 2017, 'Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure', Journal of Clinical and Experimental Neuropsychology, 39, pp. 753 - 767, http://dx.doi.org/10.1080/13803395.2016.1263282

Brew BJ; Cysique L, 2017, 'Does HIV prematurely age the brain?', The Lancet HIV, 4, pp. e380 - e381, http://dx.doi.org/10.1016/S2352-3018(17)30108-X

Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C, 2017, 'Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration (Journal of NeuroVirology, (2017), 23, 4, (539-547), 10.1007/s13365-017-0524-1)', Journal of NeuroVirology, 23, pp. 548 - 549, http://dx.doi.org/10.1007/s13365-017-0542-z

Chaganti JR; Heinecke A; Gates TM; Moffat KJ; Brew BJ, 2017, 'Functional connectivity in virally suppressed patients with HIV-associated neurocognitive disorder: A resting-state analysis', American Journal of Neuroradiology, 38, pp. 1623 - 1629, http://dx.doi.org/10.3174/ajnr.A5246

Bukhari W; Prain KM; Waters P; Woodhall M; O'Gorman CM; Clarke L; Silvestrini RA; Bundell CS; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brown M; Brownlee WJ; Butzkueven H; Carroll WM; Chen C; Coulthard A; Dale RC; Das C; Dear K; Fabis-Pedrini MJ; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Jimenez-Sanchez S; Killpatrick T; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell R; Mason DF; McCombe PA; Pender MP; Pereira JA; Pollard JD; Reddel SW; Shaw C; Spies J; Stankovich J; Sutton I; Vucic S; Walsh M; Wong RC; Yiu EM; Barnett MH; Kermode AG; Marriott MP; Parratt JDE; Slee M; Taylor BV; Willoughby E; Wilson RJ; Vincent A; Broadley SA, 2017, 'Incidence and prevalence of NMOSD in Australia and New Zealand', Journal of Neurology, Neurosurgery and Psychiatry, 88, pp. 632 - 638, http://dx.doi.org/10.1136/jnnp-2016-314839

Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C, 2017, 'White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration', Journal of NeuroVirology, 23, pp. 539 - 547, http://dx.doi.org/10.1007/s13365-017-0524-1

Kamminga J; Lal L; Wright EJ; Bloch M; Brew BJ; Cysique LA, 2017, 'Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use', Current HIV/AIDS Reports, 14, pp. 83 - 92, http://dx.doi.org/10.1007/s11904-017-0349-9

Lennon MJ; Jones SP; Lovelace MD; Guillemin GJ; Brew BJ, 2017, 'Bcl11b-A critical neurodevelopmental transcription factor-roles in health and disease', Frontiers in Cellular Neuroscience, 11, pp. 89, http://dx.doi.org/10.3389/fncel.2017.00089

Gott C; Gates T; Dermody N; Brew BJ; Cysique LA, 2017, 'Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity', PLOS ONE, 12, http://dx.doi.org/10.1371/journal.pone.0171887

Lim CK; Bilgin A; Lovejoy DB; Tan V; Bustamante S; Taylor BV; Bessede A; Brew BJ; Guillemin GJ, 2017, 'Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression', Scientific Reports, 7, http://dx.doi.org/10.1038/srep41473

Ellero J; Lubomski M; Brew B, 2017, 'Interventions for Neurocognitive Dysfunction', Current HIV/AIDS Reports, 14, pp. 8 - 16, http://dx.doi.org/10.1007/s11904-017-0346-z

Cysique LA; Gott C; Gates TM; Dermody N; Brew BJ, 2017, 'Cognitive Change Trajectories in Virally Suppressed HIV-Infected Individuals Indicate High Prevalence of Disease Activity', PLoS One, 12, pp. e0171887, http://dx.doi.org/10.1371/journal.pone.0171887

Brew B; Carroll A, 2017, 'HIV-associated neurocognitive disorders: Recent advances in pathogenesis, biomarkers, and treatment', F1000Research, 6, pp. 312, http://dx.doi.org/10.12688/f1000research.10651.1

Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ, 2017, 'Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis', Neuropharmacology, 112, pp. 346 - 364, http://dx.doi.org/10.1016/j.neuropharm.2016.05.011

Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ, 2017, 'Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases', Neuropharmacology, 112, pp. 373 - 388, http://dx.doi.org/10.1016/j.neuropharm.2016.03.024

Anesten B; Yilmaz A; Hagberg L; Zetterberg H; Nilsson S; Brew BJ; Fuchs D; Price RW; Gisslén M, 2016, 'Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV', Neurology: Neuroimmunology and NeuroInflammation, 3, http://dx.doi.org/10.1212/NXI.0000000000000300

Braidy N; Rossez H; Lim CK; Jugder BE; Brew BJ; Guillemin GJ, 2016, 'Characterization of the Kynurenine Pathway in CD8⁺ Human Primary Monocyte-Derived Dendritic Cells', Neurotoxicity Research, 30, pp. 620 - 632, http://dx.doi.org/10.1007/s12640-016-9657-x

Tobia M; Jones S; Lovelace M; Rae C; Cysique L; Brew B, 2016, 'Reduced cellular energy as a potential marker of HIV brain latency related neuropathogenesis: a pilot study', JOURNAL OF NEUROVIROLOGY, 22, pp. S76 - S77, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000394093700158&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Brew BJ, 2016, 'Has HIV-associated neurocognitive disorders now transformed into vascular cognitive impairment?', AIDS, 30, pp. 2379 - 2380, http://dx.doi.org/10.1097/QAD.0000000000001225

Bloch M; Kamminga J; Jayewardene A; Bailey M; Carberry A; Vincent T; Quan D; Maruff P; Brew B; Cysique LA, 2016, 'A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review', Clinical Infectious Diseases, 63, pp. 687 - 693, http://dx.doi.org/10.1093/cid/ciw399

Nadel J; O'Dwyer E; Emmanuel S; Huang J; Cheruvu S; Sammel N; Brew B; Otton J; Holloway CJ, 2016, 'High-risk coronary plaque, invasive coronary procedures, and cardiac events among HIV-positive individuals and matched controls', Journal of Cardiovascular Computed Tomography, 10, pp. 391 - 397, http://dx.doi.org/10.1016/j.jcct.2016.07.018

Walker S; Brew B, 2016, 'Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis', Journal of Clinical Neuroscience, 31, pp. 217 - 218, http://dx.doi.org/10.1016/j.jocn.2016.03.001

Lovelace MD; Varney B; Sundaram G; Franco NF; Ng ML; Pai S; Lim CK; Guillemin GJ; Brew BJ, 2016, 'Current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis', Frontiers in Immunology, 7, pp. 246, http://dx.doi.org/10.3389/fimmu.2016.00246

Crossley KM; Agnihotri S; Chaganti J; Rodriguez ML; McNally LP; Venna N; Turbett SE; Gutman M; Morey A; Koralnik IJ; Brew BJ, 2016, 'Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals', Journal of NeuroVirology, 22, pp. 541 - 545, http://dx.doi.org/10.1007/s13365-015-0419-y

Gray LR; Brew BJ; Churchill MJ, 2016, 'Strategies to target HIV-1 in the central nervous system', Current Opinion in HIV and AIDS, 11, pp. 371 - 375, http://dx.doi.org/10.1097/COH.0000000000000278

Brunt SJ; Cysique LA; Lee S; Burrows S; Brew BJ; Price P, 2016, 'Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?', AIDS Research and Human Retroviruses, 32, pp. 567 - 572, http://dx.doi.org/10.1089/aid.2015.0328

Gray LR; Cowley D; Welsh C; Lu HK; Brew BJ; Lewin SR; Wesselingh SL; Gorry PR; Churchill MJ, 2016, 'CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies', Molecular Psychiatry, 21, pp. 574 - 584, http://dx.doi.org/10.1038/mp.2015.111

Gates TM; Cysique LA; Siefried KJ; Chaganti J; Moffat KJ; Brew BJ, 2016, 'Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder', AIDS, 30, pp. 591 - 600, http://dx.doi.org/10.1097/QAD.0000000000000951

Lennon MJ; Jones SP; Lovelace MD; Guillemin GJ; Brew BJ, 2016, 'Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?', Neurotoxicity Research, 29, pp. 201 - 207, http://dx.doi.org/10.1007/s12640-015-9573-5

Cysique LA; Dermody N; Carr A; Brew BJ; Teesson M, 2016, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, 22, pp. 56 - 65, http://dx.doi.org/10.1007/s13365-015-0368-5

Watts J; Brew B; Tisch S, 2015, 'Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria', Journal of Clinical Neuroscience, 22, pp. 1979 - 1981, http://dx.doi.org/10.1016/j.jocn.2015.05.032

Cysique LA; Dermody N; Carr A; Brew BJ; Teesson M, 2015, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, http://dx.doi.org/10.1007/s13365-015-0368-5

Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies JM; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E, 2015, 'A new era in the treatment of multiple sclerosis', Medical Journal of Australia, 203, pp. 139 - 141, http://dx.doi.org/10.5694/mja14.01218

Jones SP; Franco NF; Varney B; Sundaram G; Brown DA; De Bie J; Lim CK; Guillemin GJ; Brew BJ, 2015, 'Expression of the kynurenine pathway in human peripheral blood mononuclear cells: Implications for inflammatory and neurodegenerative disease', PLoS ONE, 10, pp. e0131389, http://dx.doi.org/10.1371/journal.pone.0131389

Brew BJ; Robertson K; Wright EJ; Churchill M; Crowe SM; Cysique LA; Deeks S; Garcia JV; Gelman B; Gray LR; Johnson T; Joseph J; Margolis DM; Mankowski JL; Spencer B, 2015, 'HIV eradication symposium: will the brain be left behind?', Journal of NeuroVirology, 21, pp. 322 - 334, http://dx.doi.org/10.1007/s13365-015-0322-6

Britton PN; Eastwood K; Brew BJ; Nagree Y; Jones CA, 2015, 'Consensus guidelines for the investigation and management of encephalitis', Medical Journal of Australia, 202, pp. 576 - 577, http://dx.doi.org/10.5694/mja14.01042

Fois AF; Brew BJ, 2015, 'The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication', Current HIV/AIDS Reports, 12, pp. 299 - 303, http://dx.doi.org/10.1007/s11904-015-0257-9

Britton PN; Eastwood K; Paterson B; Durrheim DN; Dale RC; Cheng AC; Kenedi C; Brew BJ; Burrow J; Nagree Y; Leman P; Smith DW; Read K; Booy R; Jones CA, 2015, 'Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand', Internal Medicine Journal, 45, pp. 563 - 576, http://dx.doi.org/10.1111/imj.12749

Cysique LA; Hey-Cunningham WJ; Dermody N; Chan P; Brew BJ; Koelsch KK, 2015, 'Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition', PLoS ONE, 10, pp. e0120488, http://dx.doi.org/10.1371/journal.pone.0120488

Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CSN; Davies NNWS; Price P; Brew BJ, 2015, 'APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - A cross-sectional observational study', BMC Neurology, 15, pp. 51, http://dx.doi.org/10.1186/s12883-015-0298-0

Wright EJ; Grund B; Cysique LA; Robertson KR; Brew BJ; Collins G; Shlay JC; Winston A; Read TRH; Price RW, 2015, 'Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV MEDICINE, 16, pp. 97 - 108, http://dx.doi.org/10.1111/hiv.12238

Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E; Cooper D, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227

Inder KJ; Hussain R; Allen J; Brew B; Lewin TJ; Attia J; Kelly BJ, 2015, 'Factors associated with personal hopefulness in older rural and urban residents of New South Wales', Advances in Mental Health, 13, pp. 43 - 57, http://dx.doi.org/10.1080/18374905.2015.1039186

Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ, 2015, 'Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab', Journal of Clinical Neuroscience, http://dx.doi.org/10.1016/j.jocn.2014.08.016

Sundaram G; Brew BJ; Jones SP; Adams S; Lim CK; Guillemin GJ, 2014, 'Quinolinic acid toxicity on oligodendroglial cells: Relevance for multiple sclerosis and therapeutic strategies', Journal of Neuroinflammation, 11, http://dx.doi.org/10.1186/s12974-014-0204-5

Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ, 2014, 'Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology', PLOS ONE, 9, http://dx.doi.org/10.1371/journal.pone.0112945

Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RAL; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E, 2014, 'Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies', Journal of Clinical Neuroscience, 21, pp. 1835 - 1846, http://dx.doi.org/10.1016/j.jocn.2014.01.016

Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RAL; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E, 2014, 'Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy', Journal of Clinical Neuroscience, 21, pp. 1847 - 1856, http://dx.doi.org/10.1016/j.jocn.2014.01.018

Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RAL; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E, 2014, 'Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations', Journal of Clinical Neuroscience, 21, pp. 1857 - 1865, http://dx.doi.org/10.1016/j.jocn.2014.01.017

Chan P; Brew BJ, 2014, 'HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment', Current HIV/AIDS reports, 11, pp. 317 - 324, http://dx.doi.org/10.1007/s11904-014-0221-0

Back to profile page